-
Under PEPFAR, Matrix Labs gets OK to sell zidovudine tablets
PITTSBURGH — A subsidiary of Mylan has won approval to sell a generic drug for HIV and AIDS in developing countries under the President’s Emergency Plan for AIDS Relief.
Mylan announced Thursday that Matrix Labs won Food and Drug Administration approval for zidovudine tablets in the 100-mg strength. The drug is a generic version of ViiV Healthcare’s Retrovir, an antiretroviral sold as a water-dispersible tablet. The drug is designed to treat HIV and AIDS in children and prevent transmission of the virus from pregnant mothers to their children.
-
Lilly names new VP oncology research
INDIANAPOLIS — Eli Lilly on Thursday announced that it has named Greg Plowman VP oncology research and SVP for ImClone Systems research.
Plowman will oversee the oncology research efforts of both Lilly and ImClone, the drug maker's subsidiary that it acquired in 2008. He will report to Jan Lundberg, EVP science and technology and Lilly Research Labs president, as well as Bernhard Ehmer, ImClone president.
Prior to accepting the position at Lilly, Plowman served as senior director of research for Genentech for six years. He officially will join the company March 28.